Lebrikizumab for the treatment of asthma.

Expert Opin Investig Drugs

a Department of Surgery II-Palliative Care Nursing , University of Medicine and Pharmacy Gr.T.Popa Iasi, Iasi , Romania.

Published: October 2016

AI Article Synopsis

  • Conventional asthma treatments like inhaled corticosteroids and leukotriene inhibitors work for many patients, but some may need additional therapies due to persistent inflammation.
  • Lebrikizumab, an anti IL-13 molecule, is explored as a potential asthma treatment by targeting specific inflammation pathways.
  • Early data suggests lebrikizumab is effective for certain asthma patients, particularly those with high serum periostin levels, but further Phase III trials are needed to establish its role in personalized asthma treatment.

Article Abstract

Introduction: In asthma, most commonly, 'conventional' anti-inflammatory medications represented by inhaled corticosteroids and leukotriene inhibitors are effective. In some patients however additional inhibition of the airways inflammation is necessary. Such compounds might be molecules inhibiting specifically certain inflammation pathways and lebrikizumab an anti IL-13 molecule might represent a relevant example as a potential asthma therapy.

Areas Covered: Discussion of the rationale for the use of lebrikizumab in asthma. Analysis of the related preclinical and clinical data on lebrikizumab in asthma.

Expert Opinion: Lebrikizumab demonstrated efficacy in an asthma subset characterized by high serum periostin levels and by heavy eosinophilic inflammation. Phase III data are necessary in order to better position this therapy in asthma including as a potential personalized approach.

Download full-text PDF

Source
http://dx.doi.org/10.1080/13543784.2016.1227319DOI Listing

Publication Analysis

Top Keywords

asthma
6
lebrikizumab
5
lebrikizumab treatment
4
treatment asthma
4
asthma introduction
4
introduction asthma
4
asthma commonly
4
commonly 'conventional'
4
'conventional' anti-inflammatory
4
anti-inflammatory medications
4

Similar Publications

Cannabis consumption and risk of asthma: a systematic review and meta-analysis.

BMC Pulm Med

January 2025

Global Health and Infectious Diseases Control Institute, Nasarawa State University, Keffi, Nigeria.

Background: Cannabis is the third most widely used psychoactive substance globally, and its consumption has been increasing, particularly with the growing trend of legalization for medicinal and recreational use. Recent studies have raised concerns about the potential impact of cannabis on respiratory health, specifically the risk of asthma, a significant public health concern. This systematic review aimed to consolidate research on the association between cannabis use and the risk of asthma.

View Article and Find Full Text PDF

Methodological considerations for estimating indirect costs in children and adolescents with chronic conditions: a scoping review.

BMC Pediatr

January 2025

Chair for Institutional Economics and Health Policy, Department of Philosophy, Politics and Economics, Witten/Herdecke University, Witten, Germany.

Background: In children and adolescents, the prevalence of chronic diseases, e.g., obesity, asthma, and attention-deficit/hyperactivity disorder (ADHD), has increased in the last decades.

View Article and Find Full Text PDF

Ectopic thyroid tissue in the airway: a case report.

BMC Pulm Med

January 2025

Department of Respiratory Medicine, The Second Hospital of Jilin University, No. 4026 Yatai street, Changchun, 130041, Jilin, China.

Background: Ectopic thyroid tissue (ETT) is a rare congenital anomaly caused by the abnormal embryonic migration of thyroid tissue, leading to its presence outside its usual pretracheal location. This condition can lead to diagnostic challenges, especially when located within the airway, as it mimics other respiratory disorders such as asthma.

Case Presentation: We report the case of a 69-year-old man with endotracheal ETT presenting with severe dyspnea, and the lesion was initially suspected to be malignant.

View Article and Find Full Text PDF

A 78-years-old man was treated for asthma and pansinusitis for >5 years, and mepolizumab was initiated two years previously. Two months after the cessation of mepolizumab treatment, the asthma symptoms worsened and acute progressive muscle weakness and sensory disturbance developed. On day 8 after the onset of weakness and hypoesthesia, the patient presented with complete flaccid tetraplegia and diffuse hypoesthesia of all extremities, without paresthesia or pain, and was admitted to our hospital.

View Article and Find Full Text PDF

Under the background of climate change, the escalating air pollution and extreme weather events have been identified as risk factors for chronic respiratory diseases (CRD), causing serious public health burden worldwide. This review aims to summarize the effects of changed atmospheric environment caused by climate change on CRD. Results indicated an increased risk of CRD (mainly COPD, asthma) associated with environmental factors, such as air pollutants, adverse meteorological conditions, extreme temperatures, sandstorms, wildfire, and atmospheric allergens.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!